Lantheus (NASDAQ:LNTH) Stock Price Up 4.5% Following Analyst Upgrade

Lantheus Holdings, Inc. (NASDAQ:LNTH) shares rose 4.5% during trading on Thursday after B. Riley raised their price target on the stock from $95.00 to $99.00. B. Riley currently has a buy rating on the stock. Lantheus traded as high as $64.22 and last traded at $64.22. Approximately 151,982 shares changed hands during trading, a decline of 85% from the average daily volume of 1,046,329 shares. The stock had previously closed at $61.48.

Other analysts have also issued research reports about the stock. StockNews.com upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a research note on Saturday, January 13th. JMP Securities reiterated a “market outperform” rating and set a $100.00 price objective on shares of Lantheus in a report on Friday, February 23rd. Finally, Truist Financial restated a “buy” rating and issued a $82.00 target price (up from $80.00) on shares of Lantheus in a research note on Monday, February 26th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $104.71.

Insiders Place Their Bets

In related news, Director Mary Anne Heino sold 93,863 shares of Lantheus stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the transaction, the director now owns 251,643 shares of the company’s stock, valued at $16,434,804.33. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of Lantheus stock in a transaction on Wednesday, March 6th. The stock was acquired at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the transaction, the insider now owns 116,773,394 shares of the company’s stock, valued at approximately $110,934,724.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mary Anne Heino sold 93,863 shares of Lantheus stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the transaction, the director now directly owns 251,643 shares in the company, valued at approximately $16,434,804.33. The disclosure for this sale can be found here. In the last ninety days, insiders sold 94,545 shares of company stock valued at $6,169,936. Corporate insiders own 1.50% of the company’s stock.

Institutional Trading of Lantheus

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. increased its position in shares of Lantheus by 4.4% during the 3rd quarter. Vanguard Group Inc. now owns 7,765,120 shares of the medical equipment provider’s stock valued at $546,121,000 after purchasing an additional 326,396 shares during the last quarter. Alliancebernstein L.P. increased its holdings in Lantheus by 18.1% during the fourth quarter. Alliancebernstein L.P. now owns 3,193,302 shares of the medical equipment provider’s stock worth $162,731,000 after buying an additional 489,203 shares during the last quarter. State Street Corp raised its position in Lantheus by 0.3% in the second quarter. State Street Corp now owns 2,393,559 shares of the medical equipment provider’s stock worth $158,047,000 after acquiring an additional 7,307 shares during the period. FMR LLC boosted its stake in Lantheus by 198.2% in the third quarter. FMR LLC now owns 2,146,085 shares of the medical equipment provider’s stock valued at $149,110,000 after acquiring an additional 1,426,465 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Lantheus by 8.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,633,869 shares of the medical equipment provider’s stock valued at $101,301,000 after acquiring an additional 126,638 shares during the period. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Stock Performance

The company has a debt-to-equity ratio of 0.69, a quick ratio of 5.45 and a current ratio of 5.80. The company has a market cap of $4.37 billion, a PE ratio of 13.75 and a beta of 0.53. The company’s 50 day moving average price is $60.81 and its 200-day moving average price is $62.97.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.33 by $0.26. Lantheus had a return on equity of 63.16% and a net margin of 25.20%. The business had revenue of $354.00 million during the quarter, compared to the consensus estimate of $350.44 million. Equities research analysts anticipate that Lantheus Holdings, Inc. will post 5.72 earnings per share for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.